Education
About Us
Working with TipRanks
Follow Us
NextCure Inc (NXTC)
NASDAQ:NXTC
NXTC Stock Chart & Stats
$13.73
-$0.05(-5.92%)
At close: 4:00 PM EST
$13.73
-$0.05(-5.92%)
Day’s Range― - ―
52-Week Range$2.69 - $15.74
Previous CloseN/A
Volume33.57K
Average Volume (3M)37.58K
Market Cap
$43.89M
Enterprise Value$29.99M
Total Cash (Recent Filing)$29.11M
Total Debt (Recent Filing)$4.41M
Price to Earnings (P/E)―
Beta1.34
Next Earnings
Apr 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding3,505,621
10 Day Avg. Volume95,061
30 Day Avg. Volume37,578
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.33
Price to Sales (P/S)0.00
P/FCF Ratio-0.52
Enterprise Value/Market Cap0.68
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.52
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-8.22
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
ADC Pipeline: SIM0505 ProgressSIM0505 targets cadherin-6 with a proprietary topoisomerase I payload and cross-border clinical data (U.S. and China). Positive Phase 1 dose-escalation readouts would materially de-risk this program, validate the discovery platform and enhance partner/licensing prospects over the medium term.
ADC Pipeline: LNCB74 DevelopmentLNCB74 uses a tumor-selective cleavable linker and targets B7-H4, enabling patient selection and higher-dose cohorts. A differentiated linker/payload design and focused biomarker strategy improve chances of clinical signal and broaden the company’s ADC portfolio resilience versus reliance on a single program.
Cash Runway & Modest LeverageReported preliminary cash and marketable securities (~$41.8M) plus recent financings extend operating runway into H1 2027. Combined with modest reported leverage, this gives management more time to advance clinical milestones or secure partnerships before needing larger capital raises, reducing near-term insolvency risk.
Bears Say
No Product Revenue; Persistent LossesNextCure remains a pre-revenue developer with substantial annual operating losses and negative free cash flow. Over months this necessitates continual external funding, meaning operating plans and R&D depend on financing cycles rather than internally generated cash, a durable weakness until commercialization or sustained partnering occurs.
Equity Erosion & Negative ROESharp contraction in equity and persistently negative ROE indicates sustained value dilution from repeated financing and losses. This structural erosion reduces balance sheet flexibility and heightens shareholder dilution risk when new capital is required to fund clinical development over multiple future financing cycles.
Financing Reliance & Clinical Timing RiskThe company has executed a PIPE and launched an at-the-market program while delaying a key PoC readout. Reliance on equity raises combined with trial delays increases the probability of further dilution and extends the timeline to material value inflection, making execution and enrollment risks central to long-run outcomes.
NextCure News
NXTC FAQ
What was NextCure Inc’s price range in the past 12 months?
NextCure Inc lowest stock price was $2.69 and its highest was $15.74 in the past 12 months.
What is NextCure Inc’s market cap?
NextCure Inc’s market cap is $43.89M.
When is NextCure Inc’s upcoming earnings report date?
NextCure Inc’s upcoming earnings report date is Apr 30, 2026 which is in 57 days.
How were NextCure Inc’s earnings last quarter?
Currently, no data Available
Is NextCure Inc overvalued?
According to Wall Street analysts NextCure Inc’s price is currently Overvalued.
Does NextCure Inc pay dividends?
NextCure Inc does not currently pay dividends.
What is NextCure Inc’s EPS estimate?
NextCure Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does NextCure Inc have?
NextCure Inc has 3,505,621 shares outstanding.
What happened to NextCure Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of NextCure Inc?
Currently, no hedge funds are holding shares in NXTC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NextCure Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Hedge Fund Trend
Decreased
By 837.0 Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-34.18%
12-Months-Change
Fundamentals
Return on Equity
-116.91%
Trailing 12-Months
Asset Growth
-53.51%
Trailing 12-Months
Company Description
NextCure Inc
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4; and NC525, a novel LAIR-1 antibody which is in Preclinical trails that targets acute myeloid leukemia, blast cells, and leukemic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.
Technical Analysis
Minerva Neurosciences
―
MetaVia
―
AlphaTON Capital
―
ETHZilla Corporation
―
Aptorum Group
―
Ownership Overview
―
Insiders
6.91% Mutual Funds
45.47% Other Institutional Investors
44.77% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---